SCHEMBL6471125

SCHEMBL6471125

CC(C)(O)c1ccc(C(N)=O)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.66
SIRT6 Q8N6T7 2/20 0.41
NNMT P40261 1/20 0.38
KIT P10721 1/20 0.37
FLT3 P36888 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
TSHR P16473 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37
MC3R P41968 1/20 0.37
HCRTR1 O43613 4/20 0.37
HCRTR2 O43614 4/20 0.37
MAPK1 P28482 1/20 0.37
APP P05067 1/20 0.36
LCK P06239 1/20 0.36
CCR7 P32248 1/20 0.36
CCR6 P51684 1/20 0.36
NAMPT P43490 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30435122 1.00 KMT2A (0.66) KMT2ASIRT6NNMTKITFLT3
SCHEMBL2678960 0.87 KMT2A (0.68) KMT2ASIRT6NNMTKITFLT3
SCHEMBL2677722 0.84 KMT2A (0.74) KMT2ASIRT6NNMTKITFLT3
SCHEMBL19965699 0.81 KMT2A (0.60) KMT2ASIRT6NNMTKITFLT3
SCHEMBL19987504 0.81 KMT2A (0.60) KMT2ASIRT6NNMTKITFLT3
SCHEMBL1996711 0.79 KMT2A (1.00) KMT2ASIRT6KITFLT3MAPK1
SCHEMBL5132154 0.78 KMT2A (0.53) KMT2ASIRT6TSHRNAMPT
SCHEMBL14574591 0.77 KMT2A (0.40) KMT2AHCRTR1HCRTR2
SCHEMBL11533169 0.75 KMT2A (0.62) KMT2ASIRT6TSHRMAPK1VNN1
SCHEMBL30595907 0.73 OPRM1 (0.42) KMT2AADORA3TSHRMC4RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA KMT2A 2085/4885SIRT6 750/4885NNMT 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.